Articles nAture methods | VOL.14 NO.6 | JUNE 2017 | 607 CRISPR-Cas9 nucleases can be easily programmed to create targeted double-stranded breaks (DSBs) 1-5 , and the simplicity of this process has driven widespread adoption of this genome-editing technology 6-12 . Cas9-induced DSBs can be repaired by cellular DNA repair pathways, resulting in targeted sequence alterations in the genomes of living cells and organisms [13] [14] [15] [16] [17] . Efficient cleavage by the commonly used Streptococcus pyogenes Cas9 (SpCas9) requires 17-20 nt of complementarity between a Cas9-associated single guide RNA (sgRNA) and a target site (protospacer) 5,18-21 adjacent to a 5′-NGG protospacer adjacent motif (PAM) 5, 22, 23 .
nuclease can be raised to high levels in vitro, potentially enabling identification of sequences that may be rarely cleaved in cells. An in vitro method for characterizing Cas9 cleavage specificity using partially randomized DNA libraries biased toward specific target DNA sites has previously been described, but a limitation of this approach is that many identified sites do not actually occur in the human genome 32 .
To our knowledge, only a single in vitro genome-wide off-target identification method, Digenome-seq 33 , has been described in the literature. This approach relies on nuclease cleavage of genomic DNA, sequencing adaptor ligation to all free ends (nucleaseand non-nuclease-induced), high-throughput sequencing, and bioinformatic identification of nuclease-cleaved sites exhibiting signature uniform mapping end positions. However, Digenomeseq analysis requires a large number of reads (~400 million), and the high background of random genomic DNA reads makes it challenging to identify low-frequency nuclease-induced cleavage events.
Here we describe CIRCLE-seq, an in vitro screen for identifying genome-wide off-target cleavage sites of CRISPR-Cas9 that virtually eliminates the high background of random reads observed with Digenome-seq. This improvement enables not only substantially more sensitive off-target site detection, but it also allows researchers to deploy CIRCLE-seq more easily using widely accessible benchtop next-generation sequencing platforms. For most Cas9-guide RNA complexes tested, CIRCLE-seq can identify all off-target sites in human genomic DNA found by GUIDE-seq 29 and high-throughput gene translocation sequencing (HTGTS 30 ), two of the most sensitive previously described cell-based methods. Importantly, CIRCLE-seq also identifies new bona fide off-target sites that occur in human cells. We also show that CIRCLE-seq can identify off-target sites in the absence of a reference genome, opening the door to off-target profiling in organisms lacking full genomic sequence or outbred populations with considerable sequence heterogeneity. Lastly, we demonstrate how CIRCLE-seq can be used to identify off-target cleavage sites that are enhanced or diminished by cell-type-specific singlenucleotide polymorphisms (SNPs), demonstrating the feasibility and importance of defining personalized off-target profiles.
results overview and optimization of circle-seq
To reduce background genomic DNA reads that occur with Digenome-seq and enhance detection of desired Cas9-nucleasecleaved genomic DNA fragments, we sought to selectively sequence Cas9-cleaved genomic DNA. We designed restrictionenzyme-independent strategies to generate and enzymatically select for the conversion of randomly sheared DNA into one of two different types of covalently closed DNA structures: attachment of stem-loops to linear DNA ends ( Supplementary Fig. 1 ) or circularization of linear fragments ( Fig. 1; Supplementary  Figs. 2 and 3) . Subsequent nuclease-induced cleavage of either population of covalently closed DNA molecules at on-and offtarget sites would release free DNA ends required for subsequent adaptor-ligation and high-throughput sequencing. Comparison of these two approaches demonstrated that circularization was at least an order of magnitude more effective enriching for Cas9nuclease cleaved genomic DNA fragments than attaching stem loops to linear DNA ( Supplementary Fig. 4a ). Importantly, nearly all sites identified, starting from linear DNA fragments with hairpin ends, were also identified from circularized DNA; and read counts were strongly correlated between both methods, suggesting that circularization does not bias the range or frequency of identified off-target sites (Supplementary Fig. 4b ).
We named the circularization method CIRCLE-seq, and optimization and characterization of its technical reproducibility are described in the Supplementary Note 1 (Supplementary Figs.  3 and 5) . In contrast to other genome-wide nuclease off-target discovery methods, CIRCLE-seq uniquely enables sequencing of both sides of a single cleavage site in one DNA molecule using paired-end sequencing.
circle-seq enables sensitive in vitro detection of crisPr-cas9 off-target sites
To test the sensitivity of CIRCLE-seq, we compared off-target results of an sgRNA targeting the human HBB gene with offtarget profiles of the same sgRNA generated by the most recent and accurate version of Digenome-seq 34 . Using genomic DNA from human K562 cells, CIRCLE-seq identified not only 26 of 29 off-target sites previously seen with Digenome-seq, but also 156 new sites (Supplementary Fig. 6a ). For the three sites found by Digenome-seq but not by CIRCLE-seq, we observed supporting reads in the CIRCLE-seq data ( Supplementary Fig. 6b ), demonstrating that these sites were simply undersampled in these particular experiments. Of 156 new sites called by CIRCLE-seq but not Digenome-seq, we found that 29 also showed evidence of cleavage in the original Digenome-seq data 33 ( Supplementary  Fig. 6c ); Digenome-seq likely failed to call these sites because of stringent informatics scoring criteria required to contend with the abundant genome-wide background reads generated by this method. By contrast, we found that such background reads were rare with CIRCLE-seq ( Supplementary Fig. 6d ). Indeed, we estimate the enrichment factor of CIRCLE-seq for nuclease-cleaved sequence reads to random background reads is ~180,000-fold higher than Digenome-seq based on examination of an on-target site with the two methods and adjustment for sequencing depth (Supplementary Fig. 6d ). Start mapping positions of bidirectional CIRCLE-seq reads are consistent with the expected cleavage site of SpCas9 (3 bp before the PAM sequence) ( Supplementary Fig. 6e ); this demonstrates CIRCLE-seq's ability to map cleavage positions with nucleotide-level precision. Taken together, these results demonstrate that CIRCLE-seq possesses higher signal-to-noise ratios relative to those of Digenome-seq and using approximately 100fold fewer sequencing reads; this likely accounts for its greater sensitivity for identifying genome-wide off-target sites.
comparisons of circle-seq with cell-based off-target methods
To compare CIRCLE-seq with GUIDE-seq 29 , we assessed six different sgRNAs targeted to nonrepetitive sequences that had been previously characterized by GUIDE-seq across two different human cell lines. For these six different sgRNAs, CIRCLE-seq identified variable numbers of genome-wide off-target cleavage sites ranging in number from as few as 21 to as many as 124 ( Fig. 2 , Supplementary Note 2, and Supplementary Table 2 ) with up to six mismatches relative to the on-target site ( Supplementary  Fig. 7) . For four of the six sgRNAs, CIRCLE-seq detected all offtarget sites identified by GUIDE-seq ( Supplementary Fig. 8) ; and for two other sgRNAs, it detected all but one off-target site for each ( Supplementary Fig. 8 ). Closer examination of the CIRCLE-seq data for these experiments revealed supporting reads for these two sites but not of a sufficient number to exceed the statistical threshold for detection. In addition, these two undetected sites had been at the lower boundary of detection in our GUIDE-seq experiments. Taken together, these findings again suggest that these two off-target sites would be detected with modestly increased CIRCLE-seq sequencing depth. Importantly, for all six sgRNAs, CIRCLE-seq identified many more off-target sites than were previously found by GUIDE-seq, including sites for a sgRNA targeted to the RNF2 gene, for which we had previously been unable to identify off-target sites. We obtained Integration frequency by deep sequencing
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16:87726569-87726592+_VEGFA_site_1_16:87726569-87726592_30 similar results using CIRCLE-seq to profile four additional sgRNAs targeted to repetitive sequences that we had previously characterized by GUIDE-seq (Supplementary Note 1,  Supplementary Note 2, Supplementary Figs. 7 and 8) .
We next compared CIRCLE-seq profiles of two sgRNAs targeted to EMX1 and VEGFA that had previously been characterized by the cell-based HTGTS method. These CIRCLE-seq experiments identified 48 of the 51 off-target sites (94%) previously identified by HTGTS (Supplementary Fig. 9 ). Among the three HTGTS sites not detected by CIRCLE-seq, two were found when additional experimental replicates were performed; and the third had a low HTGTS score (Supplementary Table 3 ), suggesting that these sites would be detected with greater sequencing depth. Importantly, CIRCLE-seq also found a much greater number of off-target sites than were previously identified by HTGTS (Fig. 2c) .
off-target sites are mutated in human cells
An important question is whether novel off-target cleavage sites identified in vitro by CIRCLE-seq (and not by GUIDE-seq or HTGTS) are mutated in cells by Cas9-sgRNA complexes. Many off-target sites detected by both CIRCLE-seq and GUIDE-seq have high numbers of mapping CIRCLE-seq sequencing read counts (Fig. 3a) , which strongly suggests that GUIDE-seq primarily detects off-target sites that are among the most efficiently cleaved in vitro. By contrast, many off-target sites found only by CIRCLEseq have lower CIRCLE-seq read counts (Fig. 3a) , suggesting that these might be missed by GUIDE-seq (Supplementary Fig. 10 ). In this case, we would anticipate difficulty in validating these sites in cells using standard targeted amplicon sequencing, because the error rate of next-generation sequencing places a floor for indel mutation detection of approximately 0.1%. Thus, to determine whether novel off-target sites detected only by CIRCLE-seq (but not in our original GUIDE-seq experiments) might be cleaved in human cells, we reasoned that we could instead perform high-depth targeted amplicon sequencing using genomic DNA obtained from cell-based GUIDE-seq experiments and look for tag integration as evidence of off-target cleavage (Fig. 3b) . This strategy sidesteps the problem of the indel error rate associated with deep sequencing because tag integration occurs with a negligible background frequency, thereby permitting detection of lower frequency sites.
Using targeted tag integration sequencing, we examined 98 off-target sites found by CIRCLE-seq (but not by GUIDE-seq) for SpCas9 and sgRNAs targeted to EMX1 and VEGFA (site 1). We chose sites that exhibited a range of CIRCLE-seq read counts and numbers of mismatches relative to the on-target site ( Supplementary Table 4 ). As positive controls, we also selected a smaller set of off-target sites with variable numbers of CIRCLE-seq read counts that were found by both CIRCLEseq and GUIDE-seq (Supplementary Table 4) . Targeted amplicon sequencing revealed detection of the dsODN at all of the control off-target sites with frequencies that correlated well with GUIDE-seq read counts (Fig. 3c,d) . Notably, we also detected double-stranded oligodeoxynucleotide (dsODN) integration at 26 of the 96 novel off-target sites identified only by CIRCLE-seq analysis (Fig. 3c-e) , with frequencies in the low range (0.003 -0.2%), as expected. The locations of all tag integrations map to the expected cleavage positions 3 bp away from a PAM sequence, consistent with these sites representing bona fide off-target cleavage sites (Fig. 3f) . To further characterize the mutations observed at the CIRCLE-seq sites analyzed by targeted tag sequencing, we performed somatic variant calling. Using both the somatic variant caller MuTect and visual verification of sites with integrated genome viewer (IGV), we did not find evidence of single-nucleotide variants in our targeted tag sequencing experiments (data not shown).
reference-genome-independent off-target site discovery
Because each pair of CIRCLE-seq reads yields sequences from both sides of a single CRISPR-Cas9 nuclease cleavage site, we reasoned that our method could identify off-target sites even without a reference genome sequence. We developed a mapping-independent off-target site discovery algorithm that merges CIRCLE-seq paired-end reads and directly searches for off-target cleavage sites resembling the on-target site (see Online Methods). Using this algorithm, we identified, on average, ~99.5% of CIRCLE-seq sites detected by our standard reference-based mapping algorithm and with more than ten CIRCLE-seq reads (Supplementary Fig. 11) . Thus, CIRCLE-seq could potentially be used in a reference-independent fashion to identify off-target cleavage sites for organisms whose genome sequences are less well characterized and/or show high genetic variability (e.g., noninbred species in the wild).
Association of off-target sites with snPs
With its higher throughput, an in vitro method such as CIRCLEseq provides researchers with the opportunity to define patientspecific off-target profiles for any given Cas9-sgRNA nuclease. A previously published study described an interesting example of a single SNP influencing off-target cleavage 35 . To more broadly test whether genetic differences can influence nucleaseinduced off-target cleavage, we performed CIRCLE-seq experiments on human K562 genomic DNA with six sgRNAs we had already assessed on human HEK293 and U2OS genomic DNAs (three sgRNAs on HEK293s and three on U2OS). Although many off-target sites for these sgRNAs showed well-correlated CIRCLE-seq read counts on DNA from both cell types tested, we also observed 55 sites that were preferentially cleaved in one cell type or the other (Fig. 4a) . Further examination revealed that eight of these off-target cleavage sites harbored nonreference single-nucleotide polymorphisms (SNPs) that might account for these cell-type-specific differences in cleavage efficiencies ( Fig. 4b and Supplementary Table 5 ). Interestingly, these SNPs were located in regions of protospacer complementarity as well as the PAM.
We next sought to estimate how frequently SNPs might impact off-target cleavage efficiency. To do this, we examined the genotypes of 2,504 individuals from the 1000 Genomes Project 36 at all 1,247 off-target sites we detected with CIRCLE-seq for the six sgRNAs (targeted to standard nonrepetitive sequences). We found, on average, genetic variation in ~2.5% of these off-target sites at the individual level ( Fig. 4c) . At a population level, we found that superpopulations contained genetic variation in an average of ~20% of these off-target sites (Fig. 4c) . In addition, 50% of these off-target sites contained genetic variation for at least one individual sequenced in the 1000 Genomes Project (Fig. 4c) . These frequencies are consistent with the expectation that, given existence of ~100 million validated human SNPs in the most recent version of the dbSNP database 37 , one might expect to find an SNP in ~69% of SpCas9 off-target sites in the human genome. As expected, the range of mismatches observed at the off-target sites we examined was increased when considering diverse individual genotypes from the 1000 genomes project (Fig. 4d) n.d. are more closely matched to the intended sgRNA target sequence than the corresponding off-target site in the reference genome, suggesting that individuals with these particular genetic variations would have a higher risk of off-target cleavage at those sites (Fig. 4e) . Taken together, these results highlight the importance of considering individual genetic variation and illustrate how CIRCLE-seq might be used in future studies to produce personalized genome-wide off-target profiles.
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discussion
CIRCLE-seq has a substantially reduced rate of observed background reads, enabling it to sensitively identify off-target sites using a small fraction (~1.7%) of the total sequencing reads used with existing in vitro methods. Requiring only 4-5 million reads, the method is accessible to most labs and might be amenable to automation and scaling, particularly if the relatively large amount of genomic DNA required for each CIRCLE-seq reaction (25 µg; Supplementary Protocol) can be reduced. CIRCLE-seq might enable the production of larger data sets for training of more accurate predictive algorithms for Cas9 offtarget determination. This will require that the method be cost effectively automated and scaled to identify off-target cleavage sites and relative in vitro cleavage efficiencies for thousands of sgRNAs. Furthermore, analysis of CIRCLE-seq data coupled with large-scale cell-based off-target profiles obtained in ENCODE-characterized cell lines 38 with methods such as GUIDE-seq may make it possible to better understand the impact of chromatin accessibility and epigenetic modifications on the ability of nucleases to induce cellular DSBs. For example, an initial analysis we performed using publicly available DNase-seq data sets for U2OS cells indicated that CIRCLE-seq sites were significantly more likely to be detected by GUIDE-seq or targeted tag sequencing if located in DNaseI hypersensitive regions (P = 0.000017, odds ratio = 2.04[1.49-2.82]). However, because this analysis was only performed with a small number of sites and on only a single human cancer cell line, additional studies will be needed to further define this relationship.
For both routine and therapeutic applications of genome editing, because CIRCLE-seq is more sensitive than cell-based genome-wide off-target detection methods, we envision that CIRCLE-seq might be used as an initial screen to identify potential off-target sites that can then be verified with an orthogonal approach in nuclease-modified cells in culture or in vivo. In this study, we used targeted sequencing to search for GUIDE-seq dsODN tags to validate low-frequency sites (<0.1%) that would be challenging to identify by standard amplicon sequencing on account of the indel error rate associated with next-generation sequencing (typically ~0.1%). However, this approach is limited to cells that can be transfected with the GUIDE-seq dsODN tag. Thus, an important area for future work will be the development of alternate methods to more sensitively measure off-target mutagenesis in cells below the error rate of current high-throughput sequencing technologies. Currently, the true false-positive rate for CIRCLE-seq may be challenging to estimate because of limited detection sensitivity due to high error rates of current technologies for orthogonal validation.
Our CIRCLE-seq results provide greater support for the concept that human genetic variation can affect off-target cleavage 35 . Our findings illustrate the importance of considering individual genotypes when evaluating off-target risk and suggest that safety assessments of nucleases might ultimately include patient-specific genome-wide activity profiling. Alternatively, CIRCLE-seq performed on genomic DNA isolated from a large number of genetically diverse individuals may provide an effective strategy to define the vast majority of common and SNP-specific off-target effects for any given nuclease.
Finally, CIRCLE-seq could play an important role in further improvement of CRISPR-Cas nucleases. We recently described an engineered high-fidelity variant, SpCas9-HF1 (ref. 39) , which for sgRNAs targeted to nonrepetitive sites routinely failed to show evidence of off-target effects as judged by GUIDE-seq. A key question for future studies is whether CIRCLE-seq can identify lowfrequency SpCas9-HF1 off-target mutations that might fall below the detection limit of GUIDE-seq. If such off-target sites were found, we envision that beyond providing an important potential assay for therapeutic applications, CIRCLE-seq would also play a major role in enabling the continued refinement of approaches to improve CRISPR-Cas9 genome-wide specificities.
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